PURPOSE: To evaluate the efficacy and safety of daclizumab therapy for patients with various ophthalmologic inflammatory disorders (all having previously failed standard treatment methods). DESIGN: Retrospective, nonrandomized case series. PARTICIPANTS: Fourteen patients. METHODS: Fourteen patients were treated with daclizumab after previously failing standard treatment methods. MAIN OUTCOME MEASURES: Inflammation and visual acuity. RESULTS: Twelve of 27 (44%) eyes and 5 of 14 (36%) patients had improvement in visual acuity; 9 of 27 (33%) eyes and 5 of 14 (36%) patients had no change in visual acuity; and 6 of 27 (22%) eyes and 4 of 14 (27%) patients had continued visual loss. Based on degree of inflammation, 16 of 27 eyes (59%) had improvement, 3 of 27 (11%) eyes had no change, and 8 of 27 (30%) eyes worsened. CONCLUSIONS: Daclizumab is safe and, at least in some patients, appears to be an effective medication in the treatment of ocular inflammatory disorders.
PURPOSE: To evaluate the efficacy and safety of daclizumab therapy for patients with various ophthalmologic inflammatory disorders (all having previously failed standard treatment methods). DESIGN: Retrospective, nonrandomized case series. PARTICIPANTS: Fourteen patients. METHODS: Fourteen patients were treated with daclizumab after previously failing standard treatment methods. MAIN OUTCOME MEASURES: Inflammation and visual acuity. RESULTS: Twelve of 27 (44%) eyes and 5 of 14 (36%) patients had improvement in visual acuity; 9 of 27 (33%) eyes and 5 of 14 (36%) patients had no change in visual acuity; and 6 of 27 (22%) eyes and 4 of 14 (27%) patients had continued visual loss. Based on degree of inflammation, 16 of 27 eyes (59%) had improvement, 3 of 27 (11%) eyes had no change, and 8 of 27 (30%) eyes worsened. CONCLUSIONS:Daclizumab is safe and, at least in some patients, appears to be an effective medication in the treatment of ocular inflammatory disorders.
Authors: Steven Yeh; Keith Wroblewski; Ronald Buggage; Zhuqing Li; Shree K Kurup; Hatice Nida Sen; Sam Dahr; Pushpa Sran; George F Reed; Randy Robinson; Jack A Ragheb; Thomas A Waldmann; Robert B Nussenblatt Journal: J Autoimmun Date: 2008-06-20 Impact factor: 7.094